A randomised, double-blind, placebo-controlled, single ascending and multiple ascending dose study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of lomitapide in Japanese and Caucasian volunteers with elevated LDL-C

Aegerion Pharmaceuticals Inc0 个研究点开始时间: 2012年10月17日最近更新: 2014年3月10日

适应症

试验速览

暂无简介。

•Healthy male and female Caucasian or Japanese aged 20-45 years.
•Body mass index of 18.5-30 kg/m*2 at screening.
•Low density lipoprotein cholesterol level of at least 110 mg/dL.
•Agree to use acceptable contraception from the time of signing the informed consent until 3 months following administration of the last treatment or dose of study medication .
•Agree to comply with the requirements of the protocol.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 104
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Clinically significant disease or condition which might affect drug absorption, distribution or excretion.
•Any clinically significant laboratory abnormality, vital signs or other safety finding.
•Clinically significant electrocardiogram abnormalities.
•Positive hepatitis or HIV serology tests.
•Positive urine drug screen results.
•Positive serum ß-HCG and urine pregnancy test or lactating.
•History of alcohol or drug abuse.
•Metal handicap.
•Patients with dietary restrictions conflicting with the study standardised menus.
•Participation in a drug trial within 90 days prior to first drug administration.
•Use of any medication (including over-the-counter) within 2 weeks prior to enrolment.
•Use of any substance inhibiting cytochrome P450 within 2 weeks prior to enrolment.
•Donation of more than 500 mL of blood within 90 days prior to enrolment.
•Smoking more than 10 cigarettes (or equivalent amount of tobacco) per day and/or inability to cease smoking for the duration of the study.
•Treatment with herbal supplements 7 days prior to dosing, or use of vitamins 48 hours prior to enrolment.
•Legal incapacity or limited legal capacity at screening.
•Any circumstances or conditions which, in the opinion of the investigator, may affect full participation in the trial or compliance with the protocol.

发起方